American Vietnamese Biotech, Inc.

  • Market Cap: N/A
  • Industry: Medical Specialties
  • ISIN: VN000000AMV5
VND
2,000.00
-200 (-9.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.4 M

Shareholding (Jun 2023)

FII

0.00%

Held by 0 FIIs

DII

0

Held by 0 DIIs

Promoter

29.55%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

VND Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.09

stock-summary
Return on Equity

-0.11%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
63,555 Million
(Quarterly Results - Mar 2025)
Net Profit:
-3,387 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.33%
0%
33.33%
6 Months
-31.03%
0%
-31.03%
1 Year
-48.72%
0%
-48.72%
2 Years
-45.95%
0%
-45.95%
3 Years
-83.12%
0%
-83.12%
4 Years
-83.26%
0%
-83.26%
5 Years
-78.46%
0%
-78.46%

American Vietnamese Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-9.19%
EBIT Growth (5y)
-42.86%
EBIT to Interest (avg)
2.61
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
0.14
Tax Ratio
58.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.68%
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
9.58
EV to EBITDA
3.44
EV to Capital Employed
0.08
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.86%
ROE (Latest)
-0.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -71.46% vs 3,801.24% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -105.03% vs 48.46% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "63,555.00",
          "val2": "222,710.30",
          "chgp": "-71.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,917.60",
          "val2": "70,235.10",
          "chgp": "-84.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5,444.90",
          "val2": "5,015.50",
          "chgp": "8.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3,387.00",
          "val2": "67,285.40",
          "chgp": "-105.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.70%",
          "val2": "282.60%",
          "chgp": "-24.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 57.88% vs -30.99% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -221.74% vs -80.98% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "310,354.60",
          "val2": "196,570.10",
          "chgp": "57.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "19,689.90",
          "val2": "54,174.50",
          "chgp": "-63.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "19,650.50",
          "val2": "23,353.30",
          "chgp": "-15.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13,065.20",
          "val2": "10,732.10",
          "chgp": "-221.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13.90%",
          "val2": "165.20%",
          "chgp": "-17.91%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
63,555.00
222,710.30
-71.46%
Operating Profit (PBDIT) excl Other Income
10,917.60
70,235.10
-84.46%
Interest
5,444.90
5,015.50
8.56%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3,387.00
67,285.40
-105.03%
Operating Profit Margin (Excl OI)
36.70%
282.60%
-24.59%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -71.46% vs 3,801.24% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -105.03% vs 48.46% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
310,354.60
196,570.10
57.88%
Operating Profit (PBDIT) excl Other Income
19,689.90
54,174.50
-63.65%
Interest
19,650.50
23,353.30
-15.86%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13,065.20
10,732.10
-221.74%
Operating Profit Margin (Excl OI)
-13.90%
165.20%
-17.91%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 57.88% vs -30.99% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -221.74% vs -80.98% in Dec 2023

stock-summaryCompany CV
About American Vietnamese Biotech, Inc. stock-summary
stock-summary
American Vietnamese Biotech, Inc.
Medical Specialties
American Vietnamese Biotech Incorporation (AmviBiotech) is a Vietnam-based company engaged in the pharmaceutical industry. The Company is involved in the manufacture of medicines, vaccines and biological products. It is also involved in the manufacture of rapid diagnostic tests and ELISA kits, as well as the trading of other medical equipment and tools. In addition, the Company is active in the manufacture of cosmetic, soaps, detergents and other polishing and cleaning products. Its other activities include real estate trading, financial investment and the manufacture of plastic products. As of December 31, 2012, the Company had one wholly owned subsidiary named American - Vietnamese Biology Company Limited.
Company Coordinates stock-summary
Company Details
So 1251 QL 14, thi xa Dong Xoai , HO CHI MINH None : None
stock-summary
Tel: 84 651 3889034
stock-summary
Registrar Details